(1R)-2-((3-((4-((5-(2-((3,5-difluorophenyl)amino)-2-oxoethyl)-1,3-thiazol-2-yl)amino)-6-methoxyquinazolin-7-yl)oxy)propyl)amino)-1-methylethyl dihydrogen phosphate | 723280-54-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: (1R)-2-((3-((4-((5-(2-((3,5-difluorophenyl)amino)-2-oxoethyl)-1,3-thiazol-2-yl)amino)-6-methoxyquinazolin-7-yl)oxy)propyl)amino)-1-methylethyl dihydrogen phosphate
• 英文别名: [(2R)-1-[3-[4-[[5-[2-(3,5-difluoroanilino)-2-oxoethyl]-1,3-thiazol-2-yl]amino]-6-methoxyquinazolin-7-yl]oxypropylamino]propan-2-yl] dihydrogen phosphate
• CAS: 723280-54-4
• 化学式: C₂₆H₂₉F₂N₆O₇PS
• 分子量: 638.589
• InChiKey: IQERXKLIKQZHJE-OAHLLOKOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  43
• 可旋转键数：
  15
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  205
• 氢给体数：
  5
• 氢受体数：
  15

文献信息

• Quinazoline compounds
  申请人：Mortlock Austen Andrew

  公开号：US20060058523A1

  公开（公告）日：2006-03-16

  Quinazoline derivatives of formula (I) wherein A is 5-membered heteroaryl containing a sulphur atom and optionally containing one or more nitrogen atoms; compositions containing them, processes for their preparation and their use in therapy.

  公式（I）中的喹嗪啉衍生物，其中A是含有硫原子并可选地含有一个或多个氮原子的五元杂环芳基；包含它们的组合物，制备它们的过程以及它们在治疗中的使用。
• COMBINATION THERAPY FOR DISEASES INVOLVING ANGIOGENESIS
  申请人：Bausch & Lomb Incorporated

  公开号：EP2012878A2

  公开（公告）日：2009-01-14
• Combination Therapy for Diseases Involving Angiogenesis
  申请人：Ward Keith W.

  公开号：US20070258976A1

  公开（公告）日：2007-11-08

  A composition useful for treating, preventing, or ameliorating a disease condition involving abnormal angiogenesis comprises at least two therapeutic agents selected from the group consisting of compounds that interact with and inhibit a downstream activity of extracellular VEGF, compounds that interact with at least a VEGF receptor and render it substantially unavailable for interacting with VEGF, and compounds that reduce a level of expression of VEGF. The invention also includes a method for treating, preventing, or ameliorating a disease condition involving abnormal angiogenesis using such a composition.
• US7407946B2
  申请人：——

  公开号：US7407946B2

  公开（公告）日：2008-08-05
• [EN] COMBINATION THERAPY FOR DISEASES INVOLVING ANGIOGENESIS<br/>[FR] THÉRAPIE COMBINÉE POUR DES MALADIES IMPLIQUANT UNE ANGIOGENÈSE
  申请人：BAUSCH & LOMB

  公开号：WO2007130842A2

  公开（公告）日：2007-11-15

  [EN] A composition useful for treating, preventing, or ameliorating a disease condition involving abnormal angiogenesis comprises at least two therapeutic agents selected from the group consisting of compounds that interact with and inhibit a downstream activity of extracellular VEGF, compounds that interact with at least a VEGF receptor and render it substantially unavailable for interacting with VEGF, and compounds that reduce a level of expression of VEGF. The invention also includes a method for treating, preventing, or ameliorating a disease condition involving abnormal angiogenesis using such a composition.
  [FR] L'invention concerne une composition utile pour traiter, prévenir ou améliorer une maladie impliquant une angiogenèse anormale, laquelle composition comprend au moins deux agents thérapeutiques sélectionnés dans le groupe constitué de composés qui interagissent avec une activité avale du VEGF (facteur de croissance de l'endothélium vasculaire) extracellulaire ou inhibent celle-ci, de composés qui interagissent avec au moins un récepteur du VEGF et le rendent pratiquement indisponible pour interagir avec le VEGF et de composés qui réduisent le niveau d'expression du VEGF. L'invention concerne également un procédé servant à traiter, prévenir ou améliorer une maladie impliquant une angiogenèse anormale, lequel procédé utilise une telle composition.